Purpose The aim of the study was to evaluate the feasibility of using the hepatocyte-specific positron emission tomography (PET) tracer 2-[ 18 F]fluoro-2-deoxy-D-galactose (FDGal) as a tracer for hepatocellular carcinoma (HCC). Methods In addition to standard clinical investigations, 39 patients with known HCC or suspected of having HCC underwent a partial-body FDGal PET/CT (from base of skull to mid-thigh). Diagnosis of HCC was based on internationally approved criteria. FDGal PET/CT images were analysed for areas with high (hot spots) or low (cold spots) tracer accumulation when compared to surrounding tissue. Results Seven patients did not have HCC and FDGal PET/ CT was negative in each of them. Twenty-three patients had HCC and were included before treatment. FDGal PET/CT correctly identified 22 of these patients, which was comparable to contrast-enhanced CT. Interestingly, FDGal PET/CT was conclusive in 12 patients in whom conventional imaging techniques were inconclusive and required additional diagnostic investigations or close follow-up. Nine patients were included after treatment of HCC and in these patients FDGal PET/CT was able to distinguish between viable tumour tissue as hot spots and areas with low metabolic activity as cold spots. FDGal PET/CT detected extrahepatic disease in nine patients which was a novel finding in eight patients.
Introduction
Hepatocellular carcinoma (HCC) is a primary liver cancer derived from hepatocytes. Worldwide, HCC is the sixth most common cancer and the third cause of cancer-related death [1] . Liver cirrhosis significantly increases the lifetime risk of developing HCC and in more than 80% of the cases HCC develops in association with liver cirrhosis [2] . Advances in treatment of cirrhosis have improved the survival of these patients and HCC is now the leading cause of death in patients with cirrhosis [2] . HCC is potentially curable by liver transplantation, resection or radiofrequency ablation (RFA) [3] and the goal of surveillance programmes is to detect HCC at an early stage defined as a lesion with a diameter <20 mm [3] [4] [5] [6] . For this purpose, guidelines proposing diagnostic algorithms for optimized clinical management of the patient with an increased risk of developing HCC have been published [5, 6] . These guidelines are primarily based on radiological examinations such as contrastenhanced ultrasound (US), multiphase computer-assisted tomography (CT) and magnetic resonance imaging (MRI) [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] , but for small HCC the sensitivity of the noninvasive criteria is only around 30% [4] . Biopsy is considered gold standard, but may be difficult to obtain from small liver lesions as small lesions are difficult to target with the biopsy needle or simply cannot be visualized with US used to guide the needle [12] ; for small HCC lesions, a false-negative rate of 30% has been reported for the first fine-needle biopsy [4] . Moreover, risks are related to the invasive biopsy procedure, and the development of improved noninvasive diagnostic tools is therefore of utmost importance for better diagnosis of HCC.
Positron emission tomography (PET) with the glucose analogue 2-[ 18 F]fluoro-2-deoxy-D-glucose (FDG) is widely used in oncology, but FDG PET misses 30-50% of HCC lesions in the liver [13] [14] [15] [16] . The feasibility of using PET tracers of other metabolic pathways have been published, most recently 11 C-labelled acetate [17] [18] [19] [20] [21] , 18 F-labelled choline [22] , 11 C-labelled choline [23] and 18 F-labelled fluorothymidine [24] , but so far no studies have been convincing when using the tracers as single molecular imaging modalities. The largest prospective study with comparison of 11 C-acetate and FDG PET/CT concluded that both 11 C-acetate and FDG PET/CT as well as the two tracers used in combination had low sensitivity for the detection of small primary HCC [20] . Accordingly there is still a need for better imaging modalities for detection of HCC. A couple of decades ago, a few promising PET studies using the galactose analogue 2-[ 18 F]fluoro-2-deoxy-D-galactose (FDGal) in experimental tumour models were published [25] [26] [27] [28] , but to the best of our knowledge no FDGal PET studies of patients with HCC have been published. FDGal is a tracer for galactose metabolism and avidly accumulates in the liver compared to other tissues [29, 30] . FDGal can be synthesized using commercially available kits for FDG production with only minor modifications [31] , and the production can thus readily be implemented at most clinical PET facilities or distributed to other nearby centres due to the radioactive half-life of 110 min. In the present feasibility study, we tested the potential use of FDGal as a PET tracer for HCC in patients with or suspected of having HCC. The aim was to study the uptake pattern of FDGal in intra-and extrahepatic HCC lesions.
Materials and methods

Patients
Thirty-nine patients were enrolled. The diagnosis of HCC was based on multiphase contrast-enhanced CT (ceCT) or MRI, plasma α-fetoprotein (αFP), contrast-enhanced US and/or histopathology according to internationally approved guidelines at the time of the study [5, 6] . All investigations were performed as state-of-the-art procedures. Biopsy material was obtained from 29 patients. One patient (ID 32) had a false-negative biopsy. 
FDGal PET/CT
The patient fasted for at least 6 h before the study but was encouraged to drink water. FDGal was produced according to a previously described procedure [31] . A partial-body PET/CT recording from the base of the skull to mid-thighs was performed 70-95 min after intravenous injection of FDGal in an cubital vein (median radioactive dose was 100 MBq, range 60-262 MBq). The camera was a combined 40-slice Siemens Biograph TruePoint PET/CT camera (Siemens AG, Erlangen, Germany) with a transaxial field of view of 21 cm (5-7 bed positions, 3-min scan in each bed position). The CT scan was a low-dose CT (120 kV; mAs according to body weight: 25 mAs if ≤70 kg, 30 mAs if 70-100 kg and 50 mAs if ≥100 kg) and was reconstructed using a smooth filter and a slice thickness of 5 mm with an increment of 3 mm. PET data were reconstructed in an iterative mode using a Gaussian filter (8 mm full-width at half-maximum) and the CT scan for attenuation correction yielding images with a central spatial resolution of 9 mm. Standardized uptake values (SUV) of FDGal were calculated by normalizing the tissue concentrations of radioactivity for injected dose and body weight.
As FDGal is a novel PET tracer for human studies, we did not know the minimal tracer dose needed to achieve highquality PET images when we initiated the study. Because the effective dose of FDGal is about twice that of FDG [31] , we decided to start with a dose of 200 MBq which is half the dose normally used in FDG studies. Due to technical problems with the production of FDGal we injected 60 MBq in one patient (ID 10). The quality of the PET images from this study was good and we accordingly decided to use a dose of 100 MBq FDGal in the subsequent patients.
Image interpretation
All FDGal PET/CT images were analysed without knowledge of the clinical history of the patient and results from other imaging techniques and/or histopathology. The images were evaluated for lesions with increased or decreased uptake of FDGal compared to surrounding tissue. For an area with an increased uptake (hot spot) a tumour to background ratio (T/B ratio) was defined as the maximum SUV in that area divided by the average SUV in surrounding tissue. A T/B ratio for areas with low uptake (cold spots) were similarly noted as the minimum SUV in that area divided by the average SUV in surrounding tissue. The FDGal PET images were then analysed again by viewing them side by side with the ceCT images and/or images from other imaging modalities and with knowledge of clinical information on the patient in order to decide whether the suspicious areas on the PET images corresponded to the suspicious areas on ceCT and vice versa. Because FDGal PET is a novel imaging technique, the first 15 cases were used to build experience and these cases were therefore reviewed again blinded for patient ID.
Results
A total of 39 patients were enrolled in the study; patient characteristics are given in Table 1 . Twenty-three patients had HCC and had the FDGal PET/CT performed before receiving any treatment of the disease (Table 2) . Nine subjects were included after previous treatment for HCC (Table 3) . Seven patients were suspected of having HCC, but did not ( Table 4) .
As seen in Table 1 , alcohol (n=12) and viral hepatitis C (n=10) were dominant aetiological factors. The majority of patients with liver disease were stable being in Child-Pugh [32] class A (n=19); 9 patients were in class B, and only 4 patients were in class C. Seven patients were not classified according to the Child-Pugh score because they did not have any underlying liver disease.
Patients with HCC included before treatment
Of the 23 patients with HCC investigated before receiving any treatment, 7 patients had one or a few FDGal-positive nodules with T/B ratios between 1.2 and 1.9, i.e. hot spots ( Table 2) . For all seven patients, the FDGal PET/ CT was in accordance with other imaging modalities and clinical information. Figure 1 shows an example of a single nodule in the right liver lobe of a patient (ID 33) with severe cirrhosis. ID 22 had one large tumour with central necrosis; the T/B ratio was 1.5 in the viable tumour tissue and 0.4 in the necrotic area (Fig. 2) . In ID 27, FDGal PET/CT showed three lesions with SUV values between 1.4 and 1.8, whereas ceCT showed no lesions and MRI showed one lesion; a biopsy showed HCC and follow-up showed rapid progression with several lesions on US and the patient died 46 days later. In ID 6, FDGal PET/CT showed more suspicious areas than ceCT and follow-up showed progression in these areas.
In ten cases (Table 2) , the FDGal PET/CT images were interpreted as multinodular disease with an average T/B ratio of 1.6 (1.3-2.8). In all ten cases, the areas of increased FDGal uptake corresponded with areas identified as tumour nodules on ceCT. In ID 19, areas of necrotic tumour tissue were scattered within the large multinodular tumour. In ID 20, other imaging modalities did not suggest multinodular disease at the time that FDGal PET/CT was performed, but close follow-up showed rapid progression to multinodular disease.
In five cases, the FDGal PET/CT images revealed only areas of low FDGal uptake when compared to the surrounding liver tissue (mean T/B ratio 0.5, range 0.2-0.8). This corresponded to tumours being described as necrotic and/or hypoperfused on ceCT. FDGal PET/CT was thus able to detect tumour areas with low metabolic activity as cold spots. Figure 3 shows an example of a tumour with low metabolic activity. In one case (in ID 28), FDGal PET/CT was falsenegative, as it did not reveal any hot or cold spots, whereas both ceCT and US showed a lesion. The HCC diagnosis was confirmed by a biopsy.
Patients included after treatment of HCC
The results from the nine patients with suspected relapse after previous treatment of HCC are summarized in Table 3 . In all nine cases, FDGal PET/CT was in accordance with other imaging modalities and clinical information. In ID 39, pretreatment ceCT showed several lesions and a series of transarterial chemoembolization (TACE) was planned. FDGal PET/CT was performed after the first series and showed low uptake in the treated area (cold spot) and high uptake (hot spot) in the area still to be treated.
ID 34 had previously been treated for HCC and relapse was suspected due to the finding of a tumour mass in the left kidney on MRI. FDGal PET/CT was without any suspicious lesions in the liver and the tumour mass in the kidney did not accumulate FDGal. A biopsy showed renal cell carcinoma and the patient accordingly did not have relapse of the HCC but had developed a second cancer.
Patients without HCC
FDGal PET/CT was without any hot or cold spots in all seven cases suspected of having HCC but in whom the (Table 4) . In all cases, plasma αFP was normal (1-46 ng/ml), ceCT showed suspicious but inconclusive lesions and enhanced follow-up was necessary to reach a final diagnosis.
Extrahepatic disease
Nine of the patients had extrahepatic metastases which were FDGal PET/CT positive (Table 5 ). While the presence of extrahepatic disease was known in ID 13, it was a novel finding in the other eight cases. Figure 4 shows an example of an extrahepatic metastasis in the neck of the left femur bone.
Discussion
This paper presents the first clinical study of the potential use of FDGal PET/CT for the detection of HCC. The main ID 34 was allergic to contrast and a ceCT was not performed results are the ability of FDGal PET/CT to detect extrahepatic HCC lesions and the interesting fact that FDGal PET/CT was negative in all patients in whom HCC was suspected but the diagnosis refuted. Furthermore, FDGal PET/CT could visualize metabolically active intrahepatic HCC lesions with a T/B ratio between 1.2 and 2.8.
In patients with tumours described as being necrotic or hypoperfused on other imaging modalities, the T/B ratio of . The patient did not have cirrhosis and the aetiology was unknown. Plasma αFP was 3,047 ng/ml and the multiphase ceCT typical for HCC [5, 6] FDGal was between 0.2 and 0.8 which indicates low metabolic activity. Evaluated on a patient-to-patient basis, FDGal PET/CT was true-positive in 22 of the 23 patients with HCC who were included before treatment. This was comparable to multiphase ceCT, which was also truepositive in 22 of 23 and is used as state-of-the-art imaging modality for radiological diagnosis of HCC at many centres. Interestingly, the two imaging modalities did not miss the same patient and in combination, they correctly identified all 23 patients. In several cases, FDGal PET/CT showed definite hot spots in cases where ceCT was described as showing "suspicious areas" with the need for enhanced follow-up (Tables 2, 3 and 4) . In four cases (IDs 6, 20, 24 and 27), FDGal PET/CT detected more nodules than other imaging modalities at the time of investigation and follow-up showed rapid progression, indicating that FDGal PET/CT may be able to detect more lesions at an earlier time point than the conventional morphologically based imaging modalities. In the patients included after treatment of HCC (Table 3) , FDGal PET/CT correctly identified subjects with relapse. This promising finding suggests that FDGal PET/CT may also be useful in monitoring treatment response in patients with HCC, but this needs to be tested in a larger, prospective clinical study.
Due to the well-documented low sensitivity of FDG PET/ CT for the detection of HCC [13] [14] [15] [16] , this imaging modality is not used as a standard clinical investigation of patients with HCC at our institution. Because of this we did not consider it useful to compare FDGal PET/CT with FDG PET/CT but instead preferred to compare FDGal PET/CT with standard clinical investigations. FDGal PET/CT was true-negative in all seven patients without HCC. This indicates a high specificity of FDGal PET which is a particularly interesting finding since CT, US and/or MRI were inconclusive in all seven cases, making enhanced follow-up necessary in order to reach a final diagnosis (Table 4) . Actually, in ID 40 ceCT, MRI and US showed a The liver is large and cirrhotic with no visible tumours in this plane. Radioactivity in the kidneys is physiological due to excretion of FDGal in the urine. The patient had cirrhosis (hepatitis C) and HCC was verified by biopsy. αFP was 13 ng/ml suspicious nodule which was negative on FDGal PET/CT and a biopsy showed that it was an adenoma. Although our material is too limited to draw any robust conclusion on the general specificity of FDGal PET/CT, we find the data encouraging. Moreover, the absence of false-positive lesions on the FDGal PET/CT images is interesting with regards to common benign and premalignant changes in cirrhotic livers such as the presence of regeneration and dysplastic nodules, which complicates the radiological diagnosis of HCC [7, 8] and could be a potential source for false-positive FDGal PET/CT. However, our material indicates that FDGal does not accumulate in such nodules and a negative FDGal PET/CT thus seems to be a powerful supplement in ruling out HCC in patients with suspected HCC. In eight of the nine cases with extrahepatic disease, the presence of extrahepatic disease was unknown prior to the FDGal PET/CT (Table 5) . ID 15 had an extrahepatic metastasis in a lymph node in the common hepatobiliary ligament, which was positive on FDGal PET/CT. Enlarged lymph nodes located in the common hepatobiliary ligament are often seen in patients with cirrhosis and using conventional imaging techniques it may be difficult to evaluate whether they are benign or malignant. The maximum SUV on FDGal PET/CT was 5, which was significantly higher than the surrounding tissue creating a T/B ratio of 2.4. The metastasis was accordingly easily identified and the use of FDGal PET in conjunction with ceCT may increase the specificity of ceCT suspicious lymph nodes in that particular area.
Conclusion
Based on the present study, we believe that FDGal PET/ CT is a promising imaging modality for detection of HCC. In particular, we find the apparently high specificity of FDGal PET/CT and the ability of the method to detect extrahepatic HCC nodules interesting. The present study was a feasibility study and the clinical impact of FDGal PET/CT needs to be validated in a prospective clinical study. A key issue that needs to be studied is the potential use of FDGal PET/CT for detecting small intrahepatic HCC lesions which are poorly visualized by existing imaging methods.
